Karyopharm and promedico enter agreement to commercialize xpovio (selinexor) in israel

Karyopharm and promedico, a member of the neopharm group, enter into an exclusive distribution agreement to commercialize xpovio® (selinexor) in israel.karyopharm therapeutics - retained exclusive production rights and will supply finished product for commercial use in covered territory.karyopharm therapeutics inc - karyopharm is also eligible to receive double-digit royalties on future net sales of xpovio in covered territory.karyopharm therapeutics inc - promedico will receive exclusive rights to commercialize xpovio in covered territory.karyopharm therapeutics inc - promedico is responsible for all regulatory filings and obligations required for registering xpovio.
KPTI Ratings Summary
KPTI Quant Ranking